Author

M. M. Lieberman

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 3 Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 4 Research Focus:host-pathogen & immune response· 3 Assay:proteomics· 3 Organism:mouse· 2 Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell signaling & trafficking· 1 Research Focus:metabolism & bioenergetics· 1

Frequent Co-Authors

A. T. Lehrer· 3 shared C.-Y. Lai· 3 shared L. Pessaint· 3 shared T. A. S. Wong· 3 shared A. To· 2 shared H. Andersen· 2 shared O. Donini· 2 shared A. Cook· 1 shared

Activity by Year

2020-2024 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 35 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersImmunology

A. T. Lehrer

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

Endogenous CD28 drives CAR T cell responses in multiple myeloma

M. M. Lieberman, J. H. Tong, N. U. Odukwe, C. A. Chavel, T. J. Purdon, R. Burchett, B. M. Gillard, C. M. Brackett, A. R. McGray, J. L. Bramson, R. J. Brentjens, K. P. Lee, S. H. Olejniczak

This study shows that endogenous CD28 signaling is essential for CAR T cell efficacy in multiple myeloma, and transient CD28 blockade may reduce toxicities without compromising long-term survival.

bioRxiv · Mar 21, 2024 · PreprintCancer Biology

Protein Vaccine Induces a Durable, More Broadly Neutralizing Antibody Response in Macaques than Natural Infection with SARS-CoV-2 P.1

A. To, T. A. S. Wong, M. M. Lieberman, K. S. Thompson, L. Pessaint, J. Greenhouse, N. Daham, A. Cook, B. Narvaez, Z. Flinchbaugh, A. Van Ry, J. Yalley-Ogunro, H. Andersen, C.-Y. Lai, O. Donini, A. T. Lehrer

A recombinant subunit vaccine with CoVaccine HT adjuvant provides durable, broad neutralizing antibodies against SARS-CoV-2 VOCs in macaques, outperforming natural infection in protection and viral load reduction.

bioRxiv · Sep 24, 2021Immunology

Recombinant protein subunit SARS-CoV-2 vaccines formulated with CoVaccine HT adjuvant induce broad, Th1 biased, humoral and cellular immune responses in mice

C.-Y. Lai, A. To, T. A. S. Wong, M. M. Lieberman, D. E. Clements, J. T. Senda, A. H. Ball, L. Pessaint, H. Andersen, O. Donini, A. T. Lehrer

bioRxiv · Mar 2, 2021Immunology

CoVaccine HT™ adjuvant potentiates robust immune responses to recombinant SARS-CoV-2 Spike S1 immunisation

B. K. Haun, C.-Y. Lai, C. A. Williams, T. A. S. Wong, M. M. Lieberman, L. Pessaint, H. A. Elyard, A. T. Lehrer

This study evaluates the adjuvant CoVaccine HT in SARS-CoV-2 Spike S1 vaccines, showing it enhances IgG titres, affinity maturation, class switching, and cell-mediated immunity compared to Alhydrogel.

bioRxiv · Jul 24, 2020Immunology